top of page

BackTable / VI / Podcast / Episode #407

The Evolving Role of Drug Eluting Stents in PAD

with Dr. Eric Secemsky

In this episode of the BackTable Podcast, host Dr. Sabeen Dhand interviews Dr. Eric Secemsky about the efficacy of drug eluting technologies in vascular interventions, with Dr. Secemsky offering insight into his own practice. Dr. Secemsky is an interventional cardiologist practicing at Beth Israel Deaconess Medical Center in Boston.

Sponsored by:

Cook Medical Zilver PTX

Be part of the conversation. Put your sponsored messaging on this episode. Learn how.

The Evolving Role of Drug Eluting Stents in PAD with Dr. Eric Secemsky on the BackTable VI Podcast)
Ep 407 The Evolving Role of Drug Eluting Stents in PAD with Dr. Eric Secemsky
00:00 / 01:04

BackTable, LLC (Producer). (2024, January 22). Ep. 407 – The Evolving Role of Drug Eluting Stents in PAD [Audio podcast]. Retrieved from

BackTable CMEfy button

Stay Up To Date



Sign Up:

Podcast Contributors

Dr. Eric Secemsky discusses The Evolving Role of Drug Eluting Stents in PAD on the BackTable 407 Podcast

Dr. Eric Secemsky

Dr. Eric A. Secemsky, MD, MSc, RPVI, FACC, FSCAI, FSVM is the Director of Vascular Intervention and an Interventional Cardiologist within the CardioVascular Institute at Beth Israel Deaconess Medical Center (BIDMC).

Dr. Sabeen Dhand discusses The Evolving Role of Drug Eluting Stents in PAD on the BackTable 407 Podcast

Dr. Sabeen Dhand

Dr. Sabeen Dhand is a practicing interventional radiologist with PIH Health in Los Angeles.


Dr. Secemsky believes that drug coated technology is a game-changer in the endovascular space since it improves patient outcomes by reducing the risk of needing additional procedures. Dr. Secemsky highlights the importance of various trials such as IMPERIAL and EMINENT, which compare the effectiveness of different stents. He also speaks about the significance of the Cook Medical prediction model to calculate intervention success rates and the role of disease site-specific interventions. Dr. Secemsky ends the podcast by sharing his thoughts about advancements in the near future, including the use of bioabsorbable stents and sirolimus drug-coated balloons.


00:00 - Introduction
09:31 - Understanding Drug Coated Balloons and Stents
14:29 - The Paclitaxel Controversy
19:30 - Stenting Algorithm for Fem-Pop Disease
23:55 - Impact of Lithotripsy on Drug Delivery
26:02 - Predictability Models for Revascularization
29:14 - Economic Considerations in Drug Eluting Stent Usage
31:33 - Highlighting Trials on Drug Coated Technology and Drug Eluting Stents
37:08 - Future Technologies: Drug on Stent Grafts and Spot Stenting


Zilver PTX Cook Prediction Model:

Risk of Death Following Application of Paclitaxel‐Coated Balloons and Stents in the Femoropopliteal Artery of the Leg: A Systematic Review and Meta‐Analysis of Randomized Controlled Trials:

Durable Clinical Effectiveness With Paclitaxel-Eluting Stents in the Femoropopliteal Artery: 5-Year Results of the Zilver PTX Randomized Trial:

Mortality in randomized controlled trials using paclitaxel-coated devices for femoropopliteal interventional procedures: an updated patient-level meta-analysis:

Outcomes of Stented vs Nonstented Femoropopliteal Lesions Treated With Drug-Coated Balloon Angioplasty:

Drug coated balloon improves outcomes of sub-optimal Supera deployment in the intermediate term:

Directional Atherectomy Followed by a Paclitaxel-Coated Balloon to Inhibit Restenosis and Maintain Vessel Patency: Twelve-Month Results of the DEFINITIVE AR Study:

Intravascular Lithotripsy for Peripheral Artery Calcification: 30-Day Outcomes From the Randomized Disrupt PAD III Trial:

Efficacy of a Drug-Eluting Stent Versus Bare Metal Stents for Symptomatic Femoropopliteal Peripheral Artery Disease: Primary Results of the EMINENT Randomized Trial:

A polymer-coated, paclitaxel-eluting stent (Eluvia) versus a polymer-free, paclitaxel-coated stent (Zilver PTX) for endovascular femoropopliteal intervention (IMPERIAL): a randomized, non-inferiority trial:

SPORTS Clinical Trial Results Boston Scientific:

Please see Essential Prescribing Information for Zilver PTX here:

Use of the Zilver PTX drug-eluting peripheral stent carries the risks associated with peripheral artery stenting, including vascular complications and/or bleeding events. Refer to the Instructions for Use (IFU) for full prescribing information including information on potential adverse events, contraindications, warnings, and precautions.

Disclaimer: The Materials available on are for informational and educational purposes only and are not a substitute for the professional judgment of a healthcare professional in diagnosing and treating patients. The opinions expressed by participants of the BackTable Podcast belong solely to the participants, and do not necessarily reflect the views of BackTable.

Become a BackTable Sponsor

Up Next

Creative Solutions to OBL Misadventures with Dr. Omar Saleh and Dr. Mike Watts on the BackTable VI Podcast)
OBL or ASC for Your Private Practice? How to Decide with Teri Yates on the BackTable VI Podcast)
Site of Service Differentials with Dr. Michael Cumming on the BackTable VI Podcast)
Pros & Cons of Independence in the OBL with Dr. Mahmood Razavi and Dr. Mark Garcia on the BackTable VI Podcast)
How to Maximize Efficiency & Revenue with EMRs & Practice Management Systems with Dr. Paramjit "Romi" Chopra on the BackTable VI Podcast)
Iliofemoral Stenting: Decision-Making & Best Practices Explored with Dr. Kush Desai and Dr. Steven Abramowitz on the BackTable VI Podcast)



Atherectomy Procedure Prep
Learn about Interventional Cardiology on BackTable VI
Learn about Office-Based Lab (OBL) on BackTable VI
Peripheral Artery Disease Condition Overview
Learn about Vascular Surgery on BackTable VI

Get in touch!

We want to hear from you. Let us know if you’re interested in partnering with BackTable as a Podcast guest, a sponsor, or as a member of the BackTable Team.

Select which show(s) you would like to subscribe to:

Thanks! Message sent.

bottom of page